Post-ARDS Pulmonary Fibrosis: From Molecular Mechanisms to Clinical Management
Expert Reviews in Molecular Medicine · 2026 · 28
DOI: 10.1017/erm.2026.10077 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Reviews in Molecular Medicine, online erschienen am 03.11.2026. Verfasst von Guiyang Jia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Intensive Care Unit, The Second Affiliated Hospital of Zunyi Medical University, China. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Respiratory Distress Syndrome, COVID-19. Die Arbeit nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Acute respiratory distress syndrome (ARDS) is a severe inflammatory lung injury caused by various factors, including infection, trauma and shock. The predominant pathological alteration in its late stages is pulmonary fibrosis (PF), characterised by progressive extracellular matrix deposition, architectural destruction and functional impairment. Particularly in COVID-19-induced ARDS, PF incidence has markedly increased, making it a major sequela impacting patients’ long-term quality of life.
Methods
This review systematically examines post-acute lung injury (ALI)/ARDS PF through three perspectives: pathogenesis, prediction and treatment.
Results
Mechanistically, the fibrotic process involves epithelial injury and mesenchymal transition, fibroblast activation with aberrant extracellular matrix remodelling, dysregulated inflammation with immune cell involvement and clinical management-related factors. For prediction, various biomarkers (including growth factors, matrix proteins and inflammatory markers) and imaging features (particularly high-resolution computed tomography (HRCT) and magnetic resonance imaging (MRI) characteristics) demonstrate clinical value. Integrated multiparameter models incorporating artificial intelligence show promise for early identification and risk stratification of high-risk patients. Therapeutic strategies encompass anti-inflammatory approaches (e.g., corticosteroids and antioxidants), antifibrotic agents (pirfenidone and nintedanib), cell-based therapies (mesenchymal stem cells and exosomes) and emerging genetic/RNA interventions. However, specific preventive and therapeutic approaches tailored to the post-ALI/ARDS PF population remain inadequate in clinical practice.
Conclusions
Future research should focus on elucidating underlying mechanisms, refining early-warning systems, exploring personalised treatments and facilitating clinical translation. The ultimate goal is to transition from traditional supportive care to proactive prevention through enhanced clinical surveillance, early prediction and rational intervention, thereby preventing fibrosis progression and improving outcomes in ARDS survivors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Intensive Care Unit, The Second Affiliated Hospital of Zunyi Medical University, China.
- Intensive Care Unit, Affiliated Hospital of Zunyi Medical University, China.
ORCID-Profile: Guiyang Jia, Miao Chen, Guoyue Liu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Jia, G., Gan, Z., Feng, E., Zheng, Z., Song, E., Qian, M., Chen, M., & Liu, G. (2026). Post-ARDS Pulmonary Fibrosis: From Molecular Mechanisms to Clinical Management. Expert Reviews in Molecular Medicine, 28. https://doi.org/10.1017/erm.2026.10077
Vancouver
Jia G, Gan Z, Feng E, Zheng Z, Song E, Qian M, et al. Post-ARDS Pulmonary Fibrosis: From Molecular Mechanisms to Clinical Management. Expert Reviews in Molecular Medicine. 2026;28. doi:10.1017/erm.2026.10077
BibTeX
@article{Jia2026,
author = {Jia, Guiyang and Gan, Zhikun and Feng, Enhua and Zheng, Zhiyou and Song, Erqin and Qian, Mingjiang and Chen, Miao and Liu, Guoyue},
title = {Post-ARDS Pulmonary Fibrosis: From Molecular Mechanisms to Clinical Management},
journal = {Expert Reviews in Molecular Medicine},
year = {2026},
volume = {28},
doi = {10.1017/erm.2026.10077}
}
EUVIMED